Correlation analysis of XRCC1 gene rs25487 polymorphism and effect of concurrent neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a prospective cohort study
10.3760/cma.j.issn.0254-5098.2020.10.002
- VernacularTitle:X射线修复交叉互补基因1多态性与直肠癌新辅助放化疗疗效的前瞻性队列研究
- Author:
Weiwei CHEN
1
;
Wenling WANG
;
Gang WANG
;
Xiaokai LI
;
Guodong LI
;
Hongmin DONG
Author Information
1. 贵州医科大学 贵州医科大学附属医院 贵州省肿瘤医院腹部肿瘤科，贵阳 550001
- From:
Chinese Journal of Radiological Medicine and Protection
2020;40(10):740-745
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the correlation between the X-ray cross-complementary gene 1 (XRCC1) rs25487 gene polymorphism and the effect of neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC).Methods:This research was a prospective cohort study consisting of 55 patients with LARC who were treated in the Affiliated Hospital, Guizhou Cancer Hospital of Guizhou Medical University from August 2018 to July 2019. The XRCC1 rs25487 genotype was detected, followed by neoadjuvant chemoradiotherapy. The logistic regression with adjusted confounding factors was used to analyze the relationship between down-staging of T-stage and N-stage and XRCC1 rs25487 gene polymorphism. The stratified analysis was used to explore interactions of neutrophil lymphocyte ratio (NLR) based on logistic regression.Results:The frequencies of all genotypes were in accordance with Hardy-Weinberg equilibrium. After adjusting confounding factors, compared to patients with AA genotype, patients with GG genotype had lower rate of down-staging of T-stage after neoadjuvant radiotherapy ( OR=0.1, P<0.05). However, there was no statistically significant difference between GA and AA genotypes ( P>0.05). There was interactions between AA/GA genotypes and NLR, which affected the down-staging of T-stage after radiotherapy. Conclusions:XRCC1 rs25487 gene polymorphism is associated with the efficacy of neoadjuvant radiotherapy and concurrent system chemotherapy in patients with LARC, which may be used as a predictor of the efficacy of neoadjuvant intensive therapy.
